AstraZeneca teams up with Regeneron for obesity-busting drug pact focused on genetics

Though known more for its oncology and diabetes pipeline, AstraZeneca is now entering a new phase in obesity with a research pact penned with Regeneron.

The pair will work on and, if approved, sell small molecule compounds directed against the GPR75 target, which they will focus in on obesity and “related co-morbidities.”